WO2012169735A3 - FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물 - Google Patents

FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물 Download PDF

Info

Publication number
WO2012169735A3
WO2012169735A3 PCT/KR2012/004075 KR2012004075W WO2012169735A3 WO 2012169735 A3 WO2012169735 A3 WO 2012169735A3 KR 2012004075 W KR2012004075 W KR 2012004075W WO 2012169735 A3 WO2012169735 A3 WO 2012169735A3
Authority
WO
WIPO (PCT)
Prior art keywords
fcεri
ige
complex
water
soluble fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/004075
Other languages
English (en)
French (fr)
Other versions
WO2012169735A9 (ko
WO2012169735A2 (ko
Inventor
박병덕
윤선주
김욱동
배종환
김민희
강현정
박은혜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neopharm Co Ltd
Original Assignee
Neopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Co Ltd filed Critical Neopharm Co Ltd
Priority claimed from KR1020120054613A external-priority patent/KR20120135865A/ko
Publication of WO2012169735A2 publication Critical patent/WO2012169735A2/ko
Publication of WO2012169735A3 publication Critical patent/WO2012169735A3/ko
Publication of WO2012169735A9 publication Critical patent/WO2012169735A9/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 면역글로불린 E(IgE)의 Fc 부위에 고친화성을 갖는 수용체인 FcεRI의 수용성(soluble) 단편과 생체 적합성(biocompatibility)을 가지는 물질이 접합된 복합체에 대한 발명으로, 본 발명에 따른 FcεRI의 수용성 단편과 생체 적합성을 가지는 물질이 접합된 복합체는 IgE와 IgE 수용체인 FcεRI의 결합을 저해하여 알레르기성 사이토카인의 분비를 억제시킴으로써 알레르기 질환을 치료 및 예방하는 효과가 있다.
PCT/KR2012/004075 2011-06-07 2012-05-23 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물 Ceased WO2012169735A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0054805 2011-06-07
KR20110054805 2011-06-07
KR1020120054613A KR20120135865A (ko) 2011-06-07 2012-05-23 ＦｃεＲＩ의 수용성 단편을 포함하는 복합체 및 이를 포함하는 ＩｇＥ 매개 알레르기성 질환 치료용 조성물
KR10-2012-0054613 2012-05-23

Publications (3)

Publication Number Publication Date
WO2012169735A2 WO2012169735A2 (ko) 2012-12-13
WO2012169735A3 true WO2012169735A3 (ko) 2013-03-07
WO2012169735A9 WO2012169735A9 (ko) 2013-05-02

Family

ID=47296555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004075 Ceased WO2012169735A2 (ko) 2011-06-07 2012-05-23 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물

Country Status (1)

Country Link
WO (1) WO2012169735A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691512B (zh) 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
KR102038679B1 (ko) * 2018-01-12 2019-10-30 (주)지아이이노베이션 프로바이오틱스 및 IgE에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도
JP7579815B2 (ja) 2019-07-08 2024-11-08 ジーアイ イノベーション， インコーポレイテッド 高シアル酸含量を有し、ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100502879B1 (ko) * 1996-07-26 2005-07-25 노파르티스 아게 ＩｇＥ­결합 도메인 및 ＨＳＡ 성분을 포함하는 융합 폴리펩티드, 그의 진단 및 치료 용도
KR100464699B1 (ko) * 1995-12-18 2005-07-28 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 알레르기반응의표적치료용인키메라단백질,이의제조방법및이를포함하는약제조성물
US20050170451A1 (en) * 2001-07-19 2005-08-04 Judicial Foundation The Chemo-Sero-Therapeutic Res Human type antihuman ige receptor antibody and fragment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100464699B1 (ko) * 1995-12-18 2005-07-28 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 알레르기반응의표적치료용인키메라단백질,이의제조방법및이를포함하는약제조성물
KR100502879B1 (ko) * 1996-07-26 2005-07-25 노파르티스 아게 ＩｇＥ­결합 도메인 및 ＨＳＡ 성분을 포함하는 융합 폴리펩티드, 그의 진단 및 치료 용도
US20050170451A1 (en) * 2001-07-19 2005-08-04 Judicial Foundation The Chemo-Sero-Therapeutic Res Human type antihuman ige receptor antibody and fragment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEPHEN J. DEMAREST ET AL.: "An Intermediate pH Unfolding Transition Abrogates the Ability of IgE to IOnteract with Its High Affinity Receptor FcepcilronRlalpha", JBC, vol. 281, no. 41, 2006, pages 30755 - 30767 *

Also Published As

Publication number Publication date
WO2012169735A9 (ko) 2013-05-02
WO2012169735A2 (ko) 2012-12-13

Similar Documents

Publication Publication Date Title
PH12012500843A1 (en) Engineered anti-tslp antibody
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
MY165273A (en) Anti-cd48 antibodies and uses thereof
HK1211599A1 (en) Il-6 antagonists and uses thereof
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
PH12013501032B1 (en) Antibodies that bind il-4 and\or il-13 and their uses
WO2012131555A3 (en) Hetero-dimeric immunoglobulins
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2012058393A3 (en) Dkk1 antibodies and methods of use
MX2009010765A (es) Anticuerpos anti-ige.
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
MY160608A (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
WO2011044563A3 (en) Il-17 family cytokine compositions and uses
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
MX362089B (es) Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
WO2012138768A3 (en) Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
DK2714888T3 (da) Rekombinant gær
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
PH12015501360A1 (en) Bmp-6 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12797149

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12797149

Country of ref document: EP

Kind code of ref document: A2